embalaje : 500mg
Teléfono : +1 850 650 7790
Synonyms: Sulphabutin, Myleran, Busulphan
| Description | Busulfan is an alkylating antineoplastic agent derived from dimethane sulfonate, with cytotoxic and immunosuppressive properties. It primarily acts by forming carbonium ions in vivo, which induce cross-linking between DNA strands or between DNA and proteins, leading to DNA damage, inhibition of DNA replication, and suppression of RNA transcription. In addition, Busulfan can inhibit thioredoxin reductase and induce apoptosis. It is commonly used as a myeloablative agent in preconditioning regimens for bone marrow transplantation and can also be used to establish anemia models. |
| In vitro | Mice transplanted with busulfan exhibit slow and incomplete lymphoid engraftment. Mice treated with busulfan demonstrate a significant increase in apoptosis and a reduction in testicular weight. In NOD/SCID mice, busulfan treatment combined with irradiation achieves a detection sensitivity similar to that of limiting dilution assays. A dose-dependent lymphoid tissue reconstitution is provided in mice with 20 mg/kg to 100 mg/kg of busulfan. At 40 mg/kg, busulfan induces the maximum number of apoptotic cells while minimizing the number of necrotic cells. |
| In vivo | Busulfan, an alkylating agent that induces DNA damage through cross-linking DNA with DNA and proteins, triggers senescence in normal human diploid WI38 fibroblast cells via a cascade mediated by extracellular signal-regulated kinase (Erk) and p38 mitogen-activated protein kinase (p38 MAPK), independent of the p53-DNA damage pathway. Busulfan causes a transient reduction in glutathione levels, followed by a sustained increase in ROS production. The hypophosphorylation of Rb induced by Busulfan inhibits the expression of PCNA in testicular cells, preventing apoptosis of spermatogonial stem cells. Moreover, while Busulfan reduces the frequency of cobblestone area-forming cells, it does not significantly increase apoptosis in hematopoietic stem cells (HSC)-like cells and progenitor cells with similar phenotypes. Busulfan suppresses the hematopoietic function of HSC-like cells and progenitor cells through an apoptosis-dependent mechanism. Additionally, Busulfan-induced senescence in bone marrow hematopoietic cells correlates with a time-dependent increase in the expression of p16Ink4a and p19Arf. |
| Synonyms | Sulphabutin, Myleran, Busulphan |
| Disease Modeling Protocol | Aplastic Anemia (AA) Model
*Precautions： Mice were euthanized by cervical dislocation, and one femur was surgically removed. After obtaining the femoral epiphysis, bone marrow cells were washed away with 1 ml of PBS to prepare a bone marrow cell suspension. *References：Chen YF,et,al. The role of RIP1 and RIP3 in the development of aplastic anemia induced by cyclophosphamide and busulphan in mice. Int J Clin Exp Pathol. 2014 Dec 1;7(12):8411-20. |
| Molecular Weight | 246.30 |
| Formula | C6H14O6S2 |
| Cas No. | 55-98-1 |
| Smiles | CS(=O)(=O)OCCCCOS(C)(=O)=O |
| Relative Density. | 1.35 g/cm3 |
| Storage | Store under nitrogen Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 50.00 mg/mL (203.00 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.00 mg/mL (12.18 mM) Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
